BackRoivant Sciences Overview
Roivant Sciences Ltd

Roivant Sciences Target Price

See Roivant Sciences's analyst price targets ($40) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$37.58

Average Target Price

$40.006.4% upside

4 analysts in the last 4 months

High: $42 | Low: $36

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07H.C. WainwrightDouglas Tsao$419.1% upsideOpen
2026-05-26GuggenheimYastin Suneja$364.2% downsideOpen
2026-05-21Cowen & Co.$419.1% upsideOpen
2026-05-21Leerink PartnersDavid Risinger$4211.8% upsideOpen
2026-04-16Piper Sandler$406.4% upsideOpen
2026-03-04H.C. WainwrightDouglas Tsao$349.5% downsideOpen
2026-02-10H.C. Wainwright$3312.2% downsideOpen
2026-02-09Jefferies$3020.2% downsideOpen
2026-02-09Guggenheim$3020.2% downsideOpen
2025-12-18Guggenheim$2825.5% downsideOpen
2025-12-15Leerink PartnersDavid Risinger$3214.8% downsideOpen
2025-12-12H.C. Wainwright$2630.8% downsideOpen
2025-11-14GuggenheimYastin Suneja$2533.5% downsideOpen
2025-11-11Leerink PartnersDavid Risinger$2922.8% downsideOpen
2025-09-18Jefferies$2046.8% downsideOpen
2025-09-18Guggenheim$2144.1% downsideOpen
2025-09-18H.C. Wainwright$2046.8% downsideOpen
2024-10-21Leerink PartnersDavid Risinger$1754.8% downsideOpen
2024-09-19Goldman SachsCorinne Jenkins$1754.8% downsideOpen
2024-09-11Bank of America SecuritiesChi Fong$12.566.7% downsideOpen
2024-05-31Piper SandlerAllison Bratzel$2046.8% downsideOpen
2024-04-03H.C. WainwrightDouglas Tsao$1852.1% downsideOpen
2024-04-03Deutsche BankNeena Bitritto-Garg$1560.1% downsideOpen
2024-04-02Goldman SachsCorinne Jenkins$1852.1% downsideOpen
2024-03-13Goldman SachsCorinne Jenkins$1657.4% downsideOpen
2023-01-05Citigroup$1462.7% downsideOpen
2022-12-19Leerink Partners$1073.4% downsideOpen
2022-08-18Citigroup$1073.4% downsideOpen
2022-05-24Goldman Sachs$1268.1% downsideOpen

Roivant Sciences (ROIV) FAQ

As of the most recent data, ROIV shows a target price of $40. Scroll down for historical charts and peer comparison views.

If Roivant Sciences moved to the average analyst target of $40, shares would be roughly 6.4% higher than $37.58. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Roivant Sciences's earnings trajectory.

Besides this target price page, Stockcircle has Roivant Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $40) with ownership activity and broader fundamentals.